Outputs (81)

Factors associated with adverse COVID-19 outcomes in patients with psoriasis: insights from a global registry-based study (2020)
Journal Article
Mahil, S. K., Dand, N., Mason, K. J., Yiu, Z. Z. . N., Tsakok, T., Meynell, F., …study group, P. (2021). Factors associated with adverse COVID-19 outcomes in patients with psoriasis: insights from a global registry-based study. Journal of Allergy and Clinical Immunology, 147(1), 60-71. https://doi.org/10.1016/j.jaci.2020.10.007

BACKGROUND: The multi-morbid burden and use of systemic immunosuppressants in people with psoriasis may confer greater risk of adverse COVID-19 outcomes but data are limited. OBJECTIVE: Characterize the course of COVID-19 in psoriasis and identify fa... Read More about Factors associated with adverse COVID-19 outcomes in patients with psoriasis: insights from a global registry-based study.

Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. (2020)
Journal Article
Mahil, S., Yiu, Z., Mason, K., Dand, N., Coker, B., Wall, D., …Smith, C. (in press). Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. British Journal of Dermatology, 183(2), 404 - 406. https://doi.org/10.1111/bjd.19161

'No abstract'

Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). (2020)
Journal Article
Yiu, Z., Mason, K., Hampton, P., Reynolds, N., Smith, C., Lunt, M., …Warren, R. (2020). Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology, 183(2), 294 - 302. https://doi.org/10.1111/bjd.18981

BACKGROUND: Real-world biologic drug survival is an important proxy measure for effectiveness. Predictors of drug survival may help patients with psoriasis choose between biologic therapies.

OBJECTIVES: (i) To assess the relative drug survival of... Read More about Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR)..

Factors associated with hospitalization due to COVID‐19 in patients with psoriasis: insights from a global registry (2020)
Presentation / Conference
Mahil, S., Dand, N., Mason, K., Yiu, Z., Tsakok, T., Meynell, F., …Smith, C. (2020, July). Factors associated with hospitalization due to COVID‐19 in patients with psoriasis: insights from a global registry. Paper presented at British Association of Dermatologists 100th Annual Meeting, Virtual

Psoriasis is a common immune‐mediated inflammatory skin disease with frequent multimorbidity, and immunosuppressants are the mainstay of treatment in moderate‐to‐severe disease. An understanding of the impact of COVID‐19 on individuals with psoriasis... Read More about Factors associated with hospitalization due to COVID‐19 in patients with psoriasis: insights from a global registry.

Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study (2020)
Journal Article
Loeff, F. C., Tsakok, T., Dijk, L., Hart, M. H., Duckworth, M., Baudry, D., …Warren, R. B. (2020). Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. Journal of Investigative Dermatology, 140(11), 2129-2137. https://doi.org/10.1016/j.jid.2020.03.957

Ustekinumab is an effective treatment for psoriasis, but response varies between patients. The formation of anti-drug antibodies (ADAs) may explain part of this variation by reducing the free ustekinumab level. Currently, published analyses of the cl... Read More about Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study.

Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review (2020)
Journal Article
Al-Janabi, A., Foulkes, A. C., Mason, K., Smith, C. H., Griffiths, C. E. M., & Warren, R. B. (2020). Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. Journal of the European Academy of Dermatology and Venereology, 34(7), 1440-1448. https://doi.org/10.1111/jdv.16246

The use of biologic therapies for the treatment of chronic plaque psoriasis has been linked to the development of atopic eczema, amongst other cutaneous adverse events. This can cause diagnostic confusion and create difficulty in the management of pa... Read More about Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review.

A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. (2019)
Journal Article
Yiu, Z., Mason, K., Barker, J., Hampton, P., McElhone, K., Smith, C., …Burden, A. (in press). A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. British Journal of Dermatology, 181(6), 1265 - 1271. https://doi.org/10.1111/bjd.17849

BACKGROUND: Patients recruited in randomized controlled trials (RCTs) for biologic therapies in psoriasis are not fully representative of the real-world psoriasis population. OBJECTIVES: Firstly, to investigate whether patient characteristics are ass... Read More about A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis..

Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR) (2019)
Journal Article
Rungapiromnan, W., Mason, K., Lunt, M., McElhone, K., Burden, A., Rutter, M., …Study Group, B. (2020). Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR). Pharmacoepidemiology and Drug Safety, 34(4), 467 - 467. https://doi.org/10.1111/jdv.16018

Background
The cardiovascular safety profile of biologic therapies used for psoriasis is unclear.

Objectives
To compare the risk of major cardiovascular events (CVE s; acute coronary syndrome, unstable angina, myocardial infarction and stroke) i... Read More about Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR).

Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. (2019)
Journal Article
Rungapiromnan, W., Mason, K., Lunt, M., McElhone, K., Burden, A., Rutter, M., …Study Group, B. (2019). Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 34(4), 769 - 778. https://doi.org/10.1111/jdv.16018

BACKGROUND: The cardiovascular safety profile of biologic therapies used for psoriasis is unclear. OBJECTIVES: To compare the risk of major cardiovascular events (CVEs; acute coronary syndrome, unstable angina, myocardial infarction and stroke) in pa... Read More about Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study..

Real-world effectiveness of methotrexate, ciclosporin, acitretin and fumaric acid esters for psoriasis: Does treatment history matter? (2019)
Presentation / Conference
Mason, K. J. (2019, August). Real-world effectiveness of methotrexate, ciclosporin, acitretin and fumaric acid esters for psoriasis: Does treatment history matter?. Poster presented at 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Pennsylvania Convention Center, Philadelphia, PA, USA

Background: Real-world effectiveness of the systemic therapies methotrexate (MTX), ciclosporin (CsA), acitretin (ACI) and fumaric acid esters (FAE) prescribed to patients with moderate–severe psoriasis is poorly characterized.

Objectives: To deter... Read More about Real-world effectiveness of methotrexate, ciclosporin, acitretin and fumaric acid esters for psoriasis: Does treatment history matter?.